2nd Immunogenicity & Immunotoxicity Conference

 Kasper Lamberth, Head of the Immunogenicity Prediction and Tolerance Department at Novo Nordisk A/S, will give a featured presentation on "Using Immunogenicity Prediction Tools to Identify CD4+ T-cell Epitopes in an rFVIIa Analogue Giving Rise to ADAs?" at the 2nd  Immunogenicity and Immunotoxicity Conference to be held on January 29-31, 2014 in San Diego, CA . Dr. Lamberth will discuss the development of an rFVIIa analogue (Vatreptacog alfa) which was recently discontinued due to the development of ADAs in a phase 3 trial. The talk will present data from in silico and ex vivo immunogenicity prediction tools on full length molecules and on peptides with different length.

编辑： 小林